SCHEMBL3101068

SCHEMBL3101068

CC(C)N(C(=O)C(Cc1ccc(Cl)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.46
F2 P00734 4/20 0.44
EGFR P00533 2/20 0.43
ERBB2 P04626 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
KAT6A Q92794 3/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
BCL2 P10415 1/20 0.38
NLRP3 Q96P20 1/20 0.38
MAPK14 Q16539 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR7 P34969 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096954 0.91 LARS1 (0.45) LARS1F2KAT6AMEN1KMT2A
SCHEMBL3087740 0.89 LARS1 (0.44) LARS1F2CNR1CNR2KAT6A
SCHEMBL3102827 0.88 MEN1 (0.50) LARS1F2KAT6AMEN1KMT2A
SCHEMBL3080156 0.87 USP30 (0.49) LARS1F2KAT6AMEN1KMT2A
SCHEMBL3097728 0.85 LARS1 (0.59) LARS1F2KAT6AMEN1KMT2A
SCHEMBL3085443 0.84 PPARG (0.49) LARS1F2KAT6AMEN1KMT2A
Hydrochloric Acid SCHEMBL3080311 0.84 LARS1 (0.43) LARS1F2EGFRCNR1CNR2
SCHEMBL3092646 0.84 KAT6A (0.46) LARS1F2CNR1CNR2KAT6A
SCHEMBL3092879 0.83 LARS1 (0.42) LARS1F2KAT6AMEN1KMT2A
SCHEMBL15000247 0.82 LARS1 (0.49) LARS1F2CNR1CNR2KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885F2 4128/4885EGFR 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.